m1A/m5C/m6A/m7G调控基因预测胃癌预后及免疫关联性

被引:0
|
作者
陈小梅 [1 ,2 ]
王安奇 [1 ,2 ]
杨积祯 [3 ]
于淼 [1 ]
机构
[1] 甘肃省人民医院国家胃肠肿瘤诊治重点实验室
[2] 甘肃省人民医院临床研究与转化医学研究所
[3] 甘肃省人民医院超声医学科
关键词
m1A; m5C; m6A; m7G; 胃癌; 预后; 免疫浸润;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
摘要
目的 基于m1A/m5C/m6A/m7G甲基化调控基因建立胃癌预后风险预测模型,并分析该模型与免疫的关联性。方法 通过癌症基因组图谱(TCGA)-胃癌数据集筛选表达具有显著差异的m1A/m5C/m6A/m7G调控基因,通过单基因Cox回归分析和LASSO算法构建预后风险评分(risk score, RS)模型,使用Kaplan-Meier(K-M)统计进行RS模型验证,并应用细胞系进行RT-qPCR验证。利用单因素、多因素Cox回归分析建立nomogram模型。使用CIBERSORT算法和estimate包进行免疫关联性分析。结果 建立了基于八个甲基化调控基因的预后RS模型,将胃癌患者分为高风险和低风险。这八个基因在胃癌细胞系中高表达(P <0.05)。在TCGA-胃癌训练集和GSE62254-验证集中,患者总生存率(OS)与分组状态之间存在显著相关性(P <0.001)。nomogram生存模型预测的1年(C-index=0.703)、3年(C-index=0.729)和5年(C-index=0.734)生存率与实际生存率的一致性较好。免疫关联性分析表明,与低风险患者组相比,高风险患者组免疫评分和免疫检查点相关基因的表达较高(P <0.05)。结论 基于m1A/m5C/m6A/m7G调控基因的预后RS模型可预测胃癌预后并指导个体免疫治疗决策。
引用
收藏
页码:1230 / 1237
页数:8
相关论文
共 27 条
  • [1] Targeting TFH cells in human diseases and vaccination: rationale and practice
    Yu, Di
    Walker, Lucy S. K.
    Liu, Zheng
    Linterman, Michelle A.
    Li, Zhanguo
    [J]. NATURE IMMUNOLOGY, 2022, 23 (08) : 1157 - 1168
  • [2] Regulatory function of DNA methylation mediated lncRNAs in gastric cancer
    Li, Nan
    Zeng, Anqi
    Wang, Qian
    Chen, Maohua
    Zhu, Shaomi
    Song, Linjiang
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [3] Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
    Xu, Liangliang
    Zou, Chang
    Zhang, Shanshan
    Chu, Timothy Shun Man
    Zhang, Yan
    Chen, Weiwei
    Zhao, Caining
    Yang, Li
    Xu, Zhiyuan
    Dong, Shaowei
    Yu, Hao
    Li, Bo
    Guan, Xinyuan
    Hou, Yuzhu
    Kong, Feng-Ming
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [4] Construction and Validation of a m7G-Related Gene-Based Prognostic Model for Gastric Cancer&#13;.[J].Li Xin yu;Wang Shou lian;Chen De hu;Liu Hui;You Jian Xiong;Su Li xin;Yang Xi tao.Frontiers in Oncology.2022,
  • [5] The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma&#13;.[J].Li Dan;Li Kai;Zhang Wei;Yang Kong Wu;Mu De An;Jiang Guo Jun;Shi Rong Shu;Ke Di.Frontiers in Immunology.2022,
  • [6] N<sup>7</sup>-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis..[J].Han Hui;Yang Chunlong;Ma Jieyi;Zhang Shuishen;Zheng Siyi;Ling Rongsong;Sun Kaiyu;Guo Siyao;Huang Boxuan;Liang Yu;Wang Lu;Chen Shuang;Wang Zhaoyu;Wei Wei;Huang Ying;Peng Hao;Jiang YiZhou;Choe Junho;Lin Shuibin.Nature communications.2022, 1
  • [7] RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner
    Cai, Xianlei
    Chen, Yunhao
    Man, Da
    Yang, Beng
    Feng, Xiaode
    Zhang, Deguo
    Chen, Junru
    Wu, Jian
    [J]. CELL DEATH DISCOVERY, 2021, 7 (01)
  • [8] Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer..[J].Chen Diqun;Zhang Rouxin;Xie Aosi;Yuan Jinpeng;Zhang Jinhai;Huang Yongjian;Zhang Hongxia;Zhang Feiran.Bioengineered.2021,
  • [9] RNA methylation and cancer treatment..[J].Yang Baochen;Wang JingQuan;Tan Yao;Yuan Runzhu;Chen ZheSheng;Zou Chang.Pharmacological research.2021,
  • [10] miR-4293 upregulates lncRNA WFDC21P by suppressing mRNA-decapping enzyme 2 to promote lung carcinoma proliferation
    Zhang, Qian
    Yan, Yun-Fei
    Lv, Qing
    Li, You-Jie
    Wang, Ran-Ran
    Sun, Guang-Bin
    Pan, Li
    Hu, Jin-Xia
    Xie, Ning
    Zhang, Can
    Tian, Bao-Cheng
    Jiao, Fei
    Xu, Sen
    Wang, Ping-Yu
    Xie, Shu-Yang
    [J]. CELL DEATH & DISEASE, 2021, 12 (08)